Evaluation of the Archimedes™ System for Transparenchymal Nodule Access
| Status: | Recruiting |
|---|---|
| Conditions: | Lung Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 21 - 75 |
| Updated: | 4/21/2016 |
| Start Date: | July 2015 |
| End Date: | December 2015 |
| Contact: | Daniel Nader, D.O. |
| Phone: | (918) 286-5000 |
The Archimedes System is an image-guided navigation system used to access tissue samples in
the lungs. This study is being conducted to confirm the performance of the Archimedes System
in patients who are scheduled for standard bronchoscopy to diagnose highly suspicious lung
cancer or metastatic disease. Navigation to and sampling of the patient's lung cancer tumor
is conducted.
the lungs. This study is being conducted to confirm the performance of the Archimedes System
in patients who are scheduled for standard bronchoscopy to diagnose highly suspicious lung
cancer or metastatic disease. Navigation to and sampling of the patient's lung cancer tumor
is conducted.
Inclusion Criteria:
1. Age 21-75 years at screening
2. Highly suspicious SPN, defined as distinct nodule with a diameter of ≥8mm in its
largest dimension
3. No known endobronchial tumor
4. Tumor located anywhere in parenchymal tissue >1 cm from pleura and accessible
bronchoscopically through a POE.
5. Willing to participate in all aspects of study protocol for duration of study
6. Able to understand study requirements
7. Signs study-related informed consent document
Exclusion Criteria:
1. Any contraindication to bronchoscopy, for example:
- Untreatable life-threatening arrhythmias
- Inability to adequately oxygenate the patient during the procedure
- Acute respiratory failure with hypercapnia (unless the patient is intubated and
ventilated)
- Recent myocardial infarction
- Previously diagnosed high-grade tracheal obstruction
- Uncorrectable coagulopathy
2. Known coagulopathy
3. Platelet dysfunction or platelet count < 100 x 103 cells/mm3
4. History of major bleeding with bronchoscopy
5. Suspected pulmonary hypertension: additional testing required, such as echocardiogram
6. Moderate-to-severe pulmonary fibrosis
7. Severe emphysema or COPD: additional testing and PI consent is required
8. Bullae >5 cm located in vicinity of target SPN
9. Any other severe or life-threatening comorbidity that could increase the risk of
bronchoscopic biopsy or ATV tunneling, for example:
- ASA class > 3
- > stage 3 heart failure
- severe cachexia
- severe respiratory insufficiency or hypoxia
10. Ongoing systemic infection
11. Contraindication to general anesthesia
12. Inability to stop anticoagulants (e.g., heparin, Warfarin) or antiplatelet agents
(e.g. aspirin, clopidogrel) prior to procedure
13. Participation in any other study in last 30 days
14. Prior thoracic surgery on the same side of the lung as the SPN.
15. Breastfeeding women or females of childbearing potential with a positive pregnancy
test prior to the procedure or the intent to become pregnant during the study.
16. Life expectancy of less than one year.
17. Scheduled for lung surgery within 72hrs post-scheduled diagnostic bronchoscopy
18. Pregnancy
We found this trial at
1
site
Tulsa, Oklahoma 74133
Principal Investigator: Daniel A. Nader, D.O.
Click here to add this to my saved trials
